Cover Image
市場調查報告書

醫療事務的評價 (歐盟5國) :發炎性疾病的生技仿製藥單株抗體 (生技仿製藥 mAb)

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

出版商 FirstWord 商品編碼 326365
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
醫療事務的評價 (歐盟5國) :發炎性疾病的生技仿製藥單株抗體 (生技仿製藥 mAb) Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
出版日期: 2015年02月01日 內容資訊: 英文
簡介

本報告以英國、法國、德國、西班牙及義大利的150位風濕症醫師、皮膚科醫生,及腸胃科專門醫生為對象所實施的調查結果為基礎,提供企業的醫療事務團隊的生技仿製藥抗TNF單株抗體 (mAb) 的開發與行銷、在各種支援作用中、如何符合醫生需求的相關分析、抗TNF開發企業的醫療事務隊比較分析,為您概述為以下內容。

主要的調查內容

  • 釐清醫療事務隊的優點、缺點,確定改善的主要觀點,來自歐盟5國150位風濕症醫師、皮膚科醫生,及腸胃科專門醫生的詳細、適時的分析
  • 目前醫生和醫療事務團隊的接點調查
  • 醫生較喜歡互動的醫療事務隊的特性
  • EU5個國家的各詳細資料分析
  • 需求差距分析,FirstWord的特性分析,目前未滿足需求的確認
目錄
Product Code: 596200353

Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, ‘Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders’ offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams' roles from the originator anti-TNF companies.

Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning and communication.

With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe - France, Germany, Italy, Spain, the UK; EU5 - biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs' strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.

Key Benefits

  • Review analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists' interactions with Medical Affairs teams highlighting good and bad performance, and identifying key areas for improvement
  • Gain detailed insights on how Medical Affairs teams from originator and biosimilar anti-TNF companies can improve physician satisfaction across a range of key performance attributes
  • Understand the key areas physicians prefer to interact with Medical Affairs Teams from the originator and biosimilar anti-TNF companies
  • Identify usage of 5 originator anti-TNFs, and which products are prescribed most
  • Learn what physicians believe are the most, and least, important attributes of Medical Affairs team engagement, and how these rate across originator and biosimilar anti-TNF companies
  • Gain insights on how Medical Affairs teams can provide better service to physicians

Report Features

Filled with charts and up-to-the-minute survey analysis, this report offers:

  • Precise and timely analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists' interactions with Medical Affairs teams highlighting good and bad performance and identifying key areas for improvement
  • Examination of physicians' current touch points with Medical Affairs teams
  • Key findings regarding the attributes of Medical Affairs teams physicians value most and least
  • Detailed data broken down by each EU5 country
  • Need-Gap analysis, a proprietary analytics tool to FirstWord, identifies current unmet needs

Top Takeaways

  • Insights on the current status of support and interactions with Medical Affairs teams from the originator anti-TNF companies and biosimilar anti-TNF companies
  • Expectations of support and interactions with Medical Affairs teams from biosimilar anti-TNF companies
  • Preferred contact frequency, form and other needs from the biosimilar anti-TNF companies
Back to Top